The generic name for Movantik is naloxegol [1]. Naloxegol is a peripherally acting mu-opioid receptor antagonist used to treat opioid-induced constipation [1].
How does naloxegol work?
Naloxegol is an orally administered medication that works by blocking the effects of opioids on the mu-opioid receptors in the gastrointestinal tract [1]. Unlike some other opioid antagonists, naloxegol is designed to have limited penetration into the central nervous system, which helps to alleviate opioid-induced constipation without interfering with the pain-relieving effects of the opioids [1].
When did naloxegol become available?
Movantik, containing naloxegol, was approved by the U.S. Food and Drug Administration (FDA) in September 2014 [2].
Are there other medications for opioid-induced constipation?
Yes, other medications are available for opioid-induced constipation. These include other peripherally acting mu-opioid receptor antagonists, such as methylnaltrexone (Relistor) and naldemedine (Symproic) [3]. Patients should discuss treatment options with their healthcare provider to determine the most appropriate medication.
What are the potential side effects of naloxegol?
Common side effects reported with naloxegol include abdominal pain, diarrhea, nausea, and flatulence [1]. In rare cases, it can cause gastrointestinal perforation, which is a serious condition [1].
What is the patent status for naloxegol?
The patent landscape for naloxegol and its associated formulations can be complex. Information on specific patent expiry dates and any challenges to these patents can be found on resources like DrugPatentWatch.com [4].
Who manufactures naloxegol?
Movantik, the brand-name formulation of naloxegol, was originally developed by AstraZeneca [2]. Following acquisitions, commercial rights may have transferred.